ReviewDer Internist2005
[Rheumatology].
Review in Der Internist, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of monoclonal antibodies for the treatment of rheumatic diseases has revolutionized our understanding of therapeutic efficacy. Only a few years ago, response rates of >70% combined with significant reductions in inflammatory activity and radiologic progression would have been impossible. At the same time, however, issues of safety and cost have gained in importance and challenge physicians and patients alike. Making these new drugs available to as many eligible patients as possible requires a thorough documentation of disease activity using standardized outcome measures as well as a profound knowledge of their safety profiles. In addition, institutional guidelines for the use of these agents need to be as close to the cutting edge of science as possible. The following article presents an overview of currently available biologic agents in rheumatology and a prospect of those to come.
Indexed as
Identifiers
15997385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.